InvestSMART

Actinogen Medical Limited (ASX:ACW)

ALERT: Price-sensitive ASX Announcement for ACW
Current share price for ACW : $0.046 0.007 (17.95%)+
Announcement
Release
30 Jul 2026 10:03AM
Price at Release
$0.039
Full Release
download
Summary
Actinogen Medical Limited announced its June 2026 quarterly activity report and Appendix 4C, revealing that the XanaMIA phase 2b/3 Alzheimer's disease trial is progressing as planned, with final results expected in November 2026. The open-label extension phase has seen 88% of participants from the main trial continuing with active Xanamem therapy. Positive feedback from the European Medicines Agency aligns with prior US FDA guidance, and new patents have been secured for the treatment and manufacture of Xanamem. The company's cash position remains strong with $16.7 million, extending its financial runway beyond the trial results to mid-2027. The publication of Xanamem's positive anti-depressant activity in the British Journal of Psychiatry further validates its clinical potential.
Key Points
  • Pivotal XanaMIA phase 2b/3 Alzheimer's disease trial on track for final results in November 2026
  • 88% of main trial participants continue in open-label extension phase with Xanamem therapy
  • Positive scientific advice from European Medicines Agency aligns with US FDA
  • New patents received for Xanamem treatment and manufacturing
  • June 2026 cash balance of $16.7 million extends runway beyond trial results to mid-2027
  • Continued strong enrolment and progress in XanaMIA trial and open-label extension
  • Publication of positive anti-depressant activity of Xanamem in the British Journal of Psychiatry
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.